Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cancer Cell Detection Through In Vivo Imaging

By Drug Discovery Trends Editor | April 21, 2008

Caliper Life Sciences, Inc. introduced Bioware Ultra cell lines, a range of ultra bright light producing tumor cell lines created specifically for in vivo imaging applications. Bioware Ultra cell lines are 10 to 100 times brighter than cell lines created using traditional methods, which allows researchers to detect a single cancer cell in an animal via non-invasive in vivo imaging.

The seven cell lines covering a range of cancer models, including breast, colorectal, lung and prostate as well as lymphoma.

By tagging a tumor with the gene for luciferase, the tumor can produce light that can be monitored using Caliper’s IVIS imaging systems. As the disease progresses and reacts to specific compounds, researchers can measure tumor growth and evaluate the efficacy of compounds in real time. This ability to track disease progression in vivo offers a more conclusive understanding of how potential drugs will react in and impact humans.

Increasing the brightness of tumor producing cell lines significantly improves researchers’ ability to monitor early tumor behavior and detect micrometastases sooner. Caliper’s Bioware Ultra light producing cell lines incorporate the enhanced luc2 gene from Promega. The luc2 gene, an optimized version of luciferase for expression in mammalian cells, creates intensified visible light allowing more sensitive non-invasive detection of cells in vivo.

Caliper Life Sciences

 

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE